摘要
目的 评价达纳康(Egb761)治疗血管性认知功能障碍的临床疗效和安全性。方法 110例血管性认知功能损害的病人随机分配到治疗组和对照组;治疗组服用达纳康,每次80 mg,每日3次,而对照组服用丹参片,每次2片,每日3次,疗程均为3个月,并应用MMSE和ADL量表评价其疗效。结果 治疗组MMSE评分增加较对照组多2.38,差异有统计学意义(P<0.01);治疗组ADL评分减少较对照组多0.41,但差异无统计学意义(P>0.05)结论 达纳康治疗血管性认知功能损害安全有效。
Objective To assess the efficacy and safety of Tanakan in vascular cognitive impairment(VCI). Methods One hundred and ten patients with VCI were assigned randomly to treatment with Tanakan or Dan-shen. The test group was treated with Tanakan (80 mg Tid) and the control group was treated with Dan-shen (2 tables Tid). The duration of therapy was three months, MMSE and ADL were used to measure outcome. Results The Tanakan group had a MMSE score 2.38 points better than the Dan-shen group (P < 0.01) and an ADL score 0.41 points lower than the Dan-shen group (P >0.05). There was significant differenc between Tanakan group and Dan-shen group in VCI. Conclusions Tanakan is safe and appears capable of improving the cognitive performance of VCI patients.
出处
《卒中与神经疾病》
2004年第2期101-103,共3页
Stroke and Nervous Diseases
基金
国家自然科学基金资助项目(编号:30270483)
